Welcome to our dedicated page for Abvc Biopharma news (Ticker: ABVC), a resource for investors and traders seeking the latest updates and insights on Abvc Biopharma stock.
ABVC BioPharma, Inc. (NASDAQ: ABVC) is a clinical-stage biopharmaceutical company developing botanically based therapeutics and a medical device across oncology/hematology, central nervous system disorders, and ophthalmology. The ABVC news feed on Stock Titan brings together company-issued updates and regulatory disclosures that highlight how its pipeline and partnerships are progressing.
Readers can follow announcements on clinical milestones, such as completion of Phase II trials for CNS candidates like ABV-1504 in major depressive disorder and the advancement of ADHD Phase IIb studies at sites in the United States and Taiwan. News items also cover regulatory developments, including US FDA Investigational New Drug (IND) approvals for oncology programs targeting triple negative breast cancer, non-small cell lung cancer, myelodysplastic syndrome, and pancreatic cancer, as well as approvals from regulators in other jurisdictions.
ABVC frequently reports on global licensing agreements that shape its business model. Coverage includes multi-year deals with AiBtl BioPharma Inc. for CNS assets, ForSeeCon Eye Corporation for ophthalmology products including Vitargus®, and OncoX BioPharma Inc. for oncology and hematology products, along with related cash payments, share-based consideration, and potential royalty structures. Updates on these collaborations provide context on how ABVC seeks to translate its R&D into potential future revenue streams.
Investors can also review news about intellectual property achievements, such as patents granted in the United States, Taiwan, and Australia for Polygala extract-based CNS treatments and ophthalmology technologies, and about subsidiary activities at BioKey, Inc. and AiBtl BioPharma Inc. For an integrated view of ABVC’s evolving pipeline, licensing strategy, and financial milestones, this news page offers a centralized snapshot of the company’s publicly reported developments.
Summary not available.
ABVC BioPharma announced the initiation of site visits for its Phase II Part 2 clinical study targeting ADHD at UCSF Medical Center on March 29, 2023. This study, led by Professor Keith McBurnett, involves approximately 100 patients across the U.S. and Taiwan, with 45 participants enrolled and 37 completing the eight-week study. The study follows the successful Phase II Part 1 trial, previously accepted by the FDA in October 2020. Dr. Howard Doong emphasized the fast enrollment pace and the potential therapeutic benefits of plant-derived medicines. The ADHD market is projected to grow from $13 billion in 2022 to $15 billion by 2025.
ABVC BioPharma, a clinical-stage biopharmaceutical company, announced the successful Phase 1 Site Initiation Visit (SIV) for ABV-1601 at Cedars-Sinai Medical Center on March 31, 2023. This Phase I open-label study will evaluate the safety of PDC-1421 in 12 cancer patients experiencing moderate to severe depressive symptoms. Dr. Howard Doong, CEO, expressed satisfaction with the completed SIV and noted collaboration with three investigators from Cedars-Sinai's cancer institute to facilitate patient enrollment.
The company anticipates launching the Phase II study in Q4 2023, comparing PDC-1421's effectiveness to Wellbutrin XL. Previous trials for PDC-1421 indicated a 13.2-point reduction in depression ratings among patients, showcasing safety and tolerance. The antidepressant market, valued at $13.7 billion in 2018, is expected to grow to $15.9 billion by 2025.
ABVC BioPharma, a clinical-stage biopharmaceutical company, announced a successful Phase II Site Initiation Visit (SIV) for its product Vitargus® at Ramathibodi Hospital in Thailand on March 22, 2023. This study aims to evaluate the safety and effectiveness of Vitargus® in patients with retinal detachment compared to Sulphur Hexafluoride gas. The company is initiating patient enrollment across multiple sites, targeting at least 40 participants. Early studies show Vitargus® may enhance patient comfort and visual acuity, potentially eliminating the need for additional surgery post-treatment.
ABVC BioPharma is focused on developing innovative solutions in oncology, CNS, and ophthalmology, with an active pipeline of six drugs and the Vitargus® medical device under development.
ABVC BioPharma, Inc. reported a significant increase in revenues, generating $969,783 for the fiscal year ended December 31, 2022, up 173% from $355,797 in 2021, mainly due to increased contract services. However, operating expenses rose to $15,797,780, up 31% from $12,056,679 in the prior year, largely due to higher stock-based compensation and R&D expenses. The net loss increased by approximately 36% to $16,312,374. Cash and cash equivalents fell to $85,265 from $5,828,548. The company is progressing in clinical trials for its products, with expectations to complete Phase II trials of Vitargus by the end of 2023.
ABVC BioPharma (NASDAQ: ABVC) announced the successful Phase II Site Initiation Visit for Vitargus® at Srinagarind Hospital, Thailand, on March 9-10, 2023. The study aims to evaluate the safety and effectiveness of ABV-1701 Ocular Endotamponade in retinal detachment patients, enrolling at least 40 participants across four sites in Australia and Thailand. Vitargus® is a biodegradable vitreous substitute, improving patient comfort and visual recovery compared to existing methods. The global retinal surgery device market is projected to reach $3.7 billion by 2027, fueled by a growing elderly population. The company plans to advance its product through Phase III clinical trials.
ABVC Biopharma, Inc. (NASDAQ: ABVC) announced that its subsidiary, BioKey, received approval from the Taiwan Ministry of Health and Welfare for its Maitake Mushroom Dietary Supplement Tablet on February 6, 2023. This approval allows commercial sales in Taiwan under the brand name "DFN." The company has entered a three-year distribution agreement with Define Biotech Co. Ltd., involving $3 million in product orders. BioKey will manufacture the tablets in a controlled environment at its facility in Fremont, California. The global dietary supplements market was valued at $140.3 billion in 2020, with expected growth at a CAGR of 8.6% from 2021 to 2028.
On February 28, 2023, ABVC BioPharma (NASDAQ: ABVC) announced significant updates regarding its clinical developments in major depressive disorder (MDD), attention deficit hyperactivity disorder (ADHD), and oncology. The company completed Phase II trials for its MDD treatment, ABV-1504, and is negotiating with the FDA to begin Phase III. ABV-1505 for ADHD is in Phase II trials, expanding to UCSF soon. A Phase I study for ABV-1601 targeting cancer patient depression is set for Q1 2023. Additionally, ABVC commenced Phase II trials for pancreatic cancer treatment ABV-1703. The company expects to finalize its Vitargus Phase II trial by year-end. A recent $3.175 million financing is anticipated to support these milestones.
ABVC BioPharma (NASDAQ: ABVC) has closed a funding agreement with Lind Global Fund II, LP, securing gross proceeds of $3.175 million. The investment aims to support ongoing Phase II clinical trials for Vitargus, a medical device for retinal surgeries, and for ABV-1505, a treatment for ADHD. The agreement includes a senior convertible note of $3.704 million convertible at $1.05 per share, and a warrant for 5,291,667 shares at the same price. The financing is crucial for advancing ABVC's clinical pipeline, which includes six drugs and one medical device.
ABVC BioPharma, Inc. (NASDAQ: ABVC) announced the approval of its Phase II study for the Vitargus® medical device by the Australian Therapeutic Goods Administration (TGA) on February 9, 2023. Vitargus is the first biodegradable vitreous substitute designed to enhance patient comfort during retina reattachment surgery. The study aims to compare the safety and effectiveness of Vitargus against the commonly used SF6 Gas. It will enroll at least 40 subjects across two sites in Australia and includes hospitals in Thailand. The retinal surgery devices market is projected to reach $3.7 billion by 2027, driven by a growing geriatric population.